Jellagen Ltd announces a collaboration with the Mayo Clinic


Deprecated: strlen(): Passing null to parameter #1 ($string) of type string is deprecated in /home/medicircle/public_html/script_newsdetails.php on line 75
▴ Jellagen Ltd announces a collaboration with the Mayo Clinic
Jellagen an innovative marine biotechnology comp[any makes collagen from jellyfish

Jellagen Limited, a marine biotechnology company producing high-value collagen derived from jellyfish, has entered into a licensing agreement to grant exclusive patent rights for the development to the Mayo Clinic treatment of vocal cord paralysis.

Vocal cord paralysis (VCP) is an injury to one or both of the recurrent laryngeal nerves (RLN) that control most of the muscles in the larynx, resulting in paralysis of the vocal cord muscles, which in turn can result in l airway obstruction, dyspnoea, vocal changes, etc. Vocal cord paralysis is caused by the side effects of surgery, trauma, cancer, and more.

The original text of this announcement, written in the source language, is the authentic official version. Translations are offered solely for the convenience of the reader and must refer to the original text, which is the only legally valid text.

Jellagen, an innovative marine biotechnology company was founded in 2015 by Professor Andrew Mearns Spragg, a Scottish marine biotechnology pioneer. The idea first came to Andrew whilst surfing off the East coast of Scotland in his youth swimming through blooms of jellyfish.

Due to human activity in the oceans, jellyfish populations are now blooming. The resulting explosion in jellyfish along coastal regions is causing increasing incidents of bathers being stung, offshore aquaculture collapse and in some cases power stations to be shut down due to water inlets becoming clogged.

In the early days, Jellagen operated out of a shed in Tenby but soon moved to the Bridge Innovation Centre at Pembroke Dock. The company continued to develop its business focused on new innovative manufacturing processes and developing new products using collagen derived from jellyfish to provide a next-generation collagen biomaterial.

From those early days, Jellagen has taken up additional space at Cardiff’s Capital Business Park where it commissioned the build and installation of a bespoke collagen manufacturing facility and Quality Control laboratory which were officially launched in May 2017.

Jellagen has secured considerable investment from both private investors and public sources to develop its business. In 2019, Jellagen commercialised its jellyfish collagen cell culture products for research.

If populations of jellyfish continue to rise globally we may need to get used to living in a gelatinous world.

Tags : #JellagenLtd #MayoClinic #Jellyfish #Collagen #LatestMarineBiotechnolohy #Biotechnology #CollagenfromJellyfish

About the Author


Team Medicircle

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

Digital Identity Fraud in Healthcare: What India Must KnowNovember 18, 2026
Wearables in Clinical Care: When Should Doctors Trust the Data?November 18, 2026
Cybersecurity for Medical Startups: What Founders MissNovember 18, 2026
Remote Patient Monitoring: The Next Phase of Virtual CareNovember 18, 2026
Digital Health Wallets: Future of Medical Records in IndiaNovember 17, 2026
How Hospitals Can Prepare for a Transparent Healthcare MarketNovember 17, 2026
Childhood Nutrition: Understanding Micronutrient Gaps Beyond CaloriesNovember 16, 2026
Anaemia in Adolescent Girls: Connecting Prevention, Testing and Nutrition SupportNovember 16, 2026
Health Information Exchanges in India: Are Medical Records Finally Going Portable?November 16, 2026
Hospital Accreditation in 2026: What Is Changing Beyond the Checklist?November 16, 2026
Digital Insurance Platforms and India's Health Coverage FutureNovember 14, 2026
ABDM 2.0: India's Digital Health Ecosystem FutureNovember 14, 2026
Vaccine Cold-Chain Management: Protecting Immunisation Quality From Storage to DeliveryNovember 14, 2026
Foodborne Illness Surveillance: How Public Health Systems Track RisksNovember 14, 2026
Interoperability in Indian Healthcare: Why Patient Data Still StrugglesNovember 13, 2026
Tuberculosis Contact Screening: How Preventive Care Works Around ExposureNovember 13, 2026
COPD Care in India: Linking Diagnosis, Inhaler Education and Follow-UpNovember 13, 2026
Management of ANCA Glomerulonephritis: Induction & Maintenance ProtocolsNovember 12, 2026
Smart Hospital Command Centres Transforming IndiaNovember 12, 2026
Gamma Knife Surgery in India: What You Need to KnowNovember 12, 2026